Imatinib Mesylate from Japan
Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.628.5%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Obtain FDA approval and Drug Master File (DMF) prior to import as it's a pharmaceutical substance
• Ensure Certificate of Analysis (CoA) verifies purity >99% and compliance with USP standards
• Avoid misclassification as a research chemical; declare as bulk drug substance for medicinal use